Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis and cardiomyopathy. Currently, only limited data on serial myocardial tissue changes during treatment and whether they predict outcomes are available. Cardiac MRI (CMR) is the reference standard for non-invasive myocardial volumes/function analysis and uniquely characterizes myocardial tissue. Therefore, it may help detect myocardial tissue changes during treatment and help early treatment and prevent adverse cardiac outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Define changes in CMR tissue and blood biomarkers during ICI treatment.
Timeframe: Baseline, 6 weeks and 6 months
Investigate associations between CMR imaging biomarkers and CMR-defined left ventricular ejection fraction.
Timeframe: Baseline, 6 weeks and 6 months
Investigate associations between serum biomarkers and CMR-defined left ventricular ejection fraction.
Timeframe: Baseline, 6 weeks and 6 months